Technologies to Enhance Cell Line Productivity and Expand Antibody-Drug Conjugate Therapeutic Window to be Presented by 91㽶Ƶ Biologics at PEGS
SOMERSET, N.J. – August 25, 2020 — 91㽶Ƶ, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that two 91㽶Ƶ Biologics experts will present at the upcoming 16th Annual PEGS Boston Virtual Conference & Expo, taking place between Aug. 31 – September 4, 2020.
On Wednesday, Sept. 2 at 9:45 a.m. EDT, Gregory Bleck, Ph.D., Global Head of R&D, 91㽶Ƶ Biologics, will present “GPEx® Boost – A Novel Approach for High-Expressing CHO Cell Line Engineering” during the “Optimizing Protein Expression” stream. Dr. Bleck will explain how the next generation of 91㽶Ƶ’s GPEx cell line development technology can result in highly specific productivities, titers, and improved cell growth characteristics for most protein products.
Also on Wednesday, at 3:05 p.m. EDT, during the “Engineering Antibody-Drug Conjugates” stream, Robyn Barfield, Ph.D., Group Leader, 91㽶Ƶ Biologics, will discuss 91㽶Ƶ’s proprietary SMARTag® technology, which uses a simple, robust manufacturing process to generate stable, site-specific antibody-drug conjugates (ADCs). In her presentation, titled “Novel SMARTag Linkers Enable Better-Tolerated ADCs,” Dr. Barfield will discuss how the technology can offer wider therapeutic windows, illustrated through a comparison between 91㽶Ƶ’s anti-HER2 RED-106 ADC, and the related drug, T-DM1.
During the virtual event, Dr. Barfield will also present the case study in her presentation as a poster, “A Novel HER2-Targeted Antibody-Drug Conjugate Offers the Possibility of Clinical Dosing at Trastuzumab-Equivalent Exposure Levels.”
Dr. Bleck has more than 20 years of experience in biopharmaceutical research and development. He has a bachelor’s degree and doctorate from the University of Wisconsin-Madison and performed postdoctoral work at the University of Illinois-Urbana-Champaign, working in the areas of gene regulation and expression. At 91㽶Ƶ, Dr. Bleck has transferred his knowledge of gene expression and transgenic systems to the development and continued optimization of retrovector expression systems and development of the proprietary GPEx process.
Dr. Barfield has more than 10 years’ experience working in bioconjugation, and joined 91㽶Ƶ Biologics when it acquired Redwood Bioscience in 2014. She has a doctorate in cell and molecular biology from the University of Pennsylvania School of Medicine and a bachelor’s degree in genetics and cell biology, from the University of Georgia.
The event’s presentations and panel discussions will be available to view on-demand through the conference platform. For more information about the event, please visit biologics.catalent.com/events/pegs-boston/.
91㽶Ƶ, GPEx and SMARTag are registered trademarks of 91㽶Ƶ. or its affiliates or subsidiaries.
About 91㽶Ƶ Biologics
91㽶Ƶ Biologics is a global leader in development, manufacturing and analytical services for new biological entities, cell and gene therapies, biosimilars, sterile injectables, and antibody-drug conjugates. With over 20 years of proven expertise, 91㽶Ƶ Biologics has worked with 600+ mAbs and 80+ proteins, produced 13 biopharmaceutical drugs using GPEx® cell line development technology, and manufactured 35+ commercially approved products. 91㽶Ƶ Cell & Gene Therapy, a unit of 91㽶Ƶ Biologics, is a full-service partner for adeno-associated virus (AAV) vectors and CAR-T immunotherapies, with deep experience in viral vector scale-up and production. 91㽶Ƶ recently acquired MaSTherCell, adding expertise in autologous and allogeneic cell therapy development and manufacturing. 91㽶Ƶ Cell & Gene Therapy has produced 100+ cGMP batches across 70+ clinical and commercial programs. For more information, visit
ABOUT CATALENT
91㽶Ƶ is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, 91㽶Ƶ has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. 91㽶Ƶ employs over 13,500 people, including over 2,400 scientists and technicians, at more than 40 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. 91㽶Ƶ is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com